uniQure N.V. — FY 2016 Form 10-K
Business context and period. The filing covers the fiscal year ended December 31, 2016; it is an annual report, not a quarterly filing. uniQure is a gene-therapy developer with no U.S.-approved products. Its key programs were AMT-060 for hemophilia B, AMT-130 for Huntington’s disease, and cardiovascular programs partnered with Bristol Myers Squibb (BMS). Glybera was authorized in the EU under exceptional circumstances.
Financial performance and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $25.1 million | $10.6 million |
| Research and development expense | $72.5 million | $59.1 million |
| Selling, general and administrative expense | $26.0 million | $23.4 million |
| Loss from operations | $71.9 million | $71.2 million |
| Net loss | $73.4 million | $82.1 million |
| Basic and diluted loss per share | $2.93 | $3.72 |
| Cash and cash equivalents at year-end | $132.5 million | $221.6 million |
| Outstanding debt at year-end | $20.2 million | $20.4 million |
Revenue consisted principally of collaboration and license revenue, not material product sales: $17.0 million from BMS and $8.1 million from Chiesi. FY 2016 operating cash use was $72.2 million; investing cash use was $17.8 million, largely reflecting facility build-outs. Cash fell by $89.1 million during the year. Current assets were $143.9 million and current liabilities $22.7 million. The filing reports no useful positive profit margins; the company remained loss-making.
Q4 2016: Revenue was $9.1 million, net loss $14.7 million, and loss per share $0.58, compared with revenue of $3.9 million, net loss of $16.9 million, and loss per share of $0.69 in Q4 2015.
Material changes and notable developments
- Revenue increased from $10.6 million to $25.1 million, driven mainly by BMS collaboration activity and recognition of deferred collaboration/license consideration. Operating expenses rose to $98.5 million from $82.5 million.
- Net loss narrowed from $82.1 million to $73.4 million. The prior-year result included $7.6 million of net derivative losses; 2016 included $0.8 million of derivative gains. Operating loss was slightly higher in 2016.
- Management announced a strategic restructuring in November 2016, prioritizing hemophilia B, Huntington’s disease and BMS cardiovascular programs; deprioritizing Sanfilippo B and Parkinson’s disease; and consolidating manufacturing at Lexington, Massachusetts. Planned 2017 reductions were approximately 50–55 non-executive positions and four executives. Management expected $5–$6 million of annual operating-cost savings from 2018.
- AMT-060 Phase I/II data showed improved FIX activity and reduced bleeding and replacement-therapy use in the small 10-patient study. The filing reported no severe adverse events; three patients had mild, asymptomatic ALT elevations treated with corticosteroids. FDA Breakthrough Therapy designation was granted in January 2017, after the reporting period.
Outlook, risks, and contingencies
- Management expected year-end cash to fund operations into 2019 and stated it covered at least the next 12 months, including capital spending and debt obligations. This is not a guarantee; management also expected continued losses and said additional financing would likely be needed.
- The company planned to prepare for a pivotal AMT-060 trial, advance AMT-130 toward IND-enabling work, and continue BMS-related programs. The filing gives no specific revenue or earnings guidance.
- Key risks include clinical and regulatory failure or delay, limited rare-disease patient populations, uncertain reimbursement and pricing, dependence on BMS and Chiesi, intellectual-property licensing, and competition.
- Manufacturing transfer and qualification at Lexington could delay development or commercialization. The Amsterdam manufacturing facility was expected to be decommissioned in 2017; the company also had a 16-year Amsterdam lease and expected to seek subtenants for unused space.
- The Hercules facility carried $20.2 million of outstanding borrowings, with principal repayment scheduled from December 2017 through May 2020. The loan is secured by substantially all assets and includes restrictive covenants; the company reported covenant compliance at year-end.
- Contractual commitments included $39.4 million of operating lease payments and $24.8 million of debt payments including interest and fees. InoCard contingent consideration had a $1.8 million recorded fair value, while the nominal milestone amount was $15.3 million. The Glybera-related Dutch government grant had a contingent balance of $6.8 million, repayable from related revenues under specified terms.
- The $2.9 million Extera arbitration settlement was agreed in December 2016 and paid; the filing reports no ongoing legal proceedings. Glybera remained subject to EU post-approval obligations, and the company had not pursued U.S. approval.
Most important facts for investors to verify
- Whether the AMT-060 results hold with longer follow-up and support the planned pivotal-trial design and regulatory path.
- Lexington facility qualification, manufacturing comparability requirements, and the cost and timing of transferring production from Amsterdam.
- Cash burn, the assumptions behind the stated runway, and whether additional financing or partner payments will be required.
- Execution of restructuring and cost savings, plus the financial impact of the long-term Amsterdam lease and any subleasing.
- BMS and Chiesi program progress, milestone conditions, and the extent to which revenue depends on partner activity and reimbursement.
The financial statements were audited by PricewaterhouseCoopers Accountants N.V., which issued an unqualified opinion. The filing states that historical financial information was presented under U.S. GAAP and in U.S. dollars following the company’s transition to U.S. domestic filer status.